

SUPPLEMENTARY MATERIAL

Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review

Jonathan A. Bernstein • Jean-Pierre Llanos • Gillian Hunter • Neil Martin • Christopher S. Ambrose

J. A. Bernstein (**ORCID:** 0000-0002-3476-1196)

Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of Cincinnati, Cincinnati, OH, USA, and Bernstein Clinical Research Center, Cincinnati, OH, USA

J. -P. Llanos (**ORCID:** 0000-0002-7785-6881)

Global Medical Affairs, Amgen, Thousand Oaks, CA, USA

G. Hunter

Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

N. Martin

Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK, and University of Leicester, Leicester, UK

C. S. Ambrose (**ORCID:** 0000-0003-4175-7336)

Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA

Correspondence

Christopher S. Ambrose, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA.

Email: chris.ambrose@astrazeneca.com

Table S1 PubMed search string

(asthma[Title] OR asthmatic[title])
AND
(severe[Title/Abstract] OR uncontrolled[Title/Abstract] OR poorly controlled[Title/Abstract] OR inadequately controlled[Title/Abstract])
AND
(allergy[Title] OR allergic[Title] OR atopy[Title] OR atopic[Title])
AND
(tezepelumab[Title] OR dupilumab[Title] OR benralizumab[Title] OR mepolizumab[Title] OR reslizumab[Title] OR omalizumab[Title] OR biologic[Title] OR monoclonal[Title] OR anti-[Title])
AND
(eosinophil[Title/Abstract] OR eosinophils[Title/Abstract] OR eosinophilic[Title/Abstract])
AND
(exacerbation[Title/Abstract] OR exacerbations[Title/Abstract])